For anyone who has spent time following the opioid crisis, the pattern is by now familiar. A new synthetic substance enters the illicit drug supply. It is more potent than what came before it. It spreads faster than the public health infrastructure can track. The death toll rises before the awareness does. And by the time most families, first responders, and community members understand what they are dealing with, the drug has already become a fixture of the supply.

Fentanyl followed that pattern. Xylazine-adulterated opioids, known as tranq dope, followed it again. Now, a class of synthetic opioids called nitazenes is following it a third time, and Pennsylvania is once again near the front of the problem.

Understanding nitazenes clearly, what they are, what they do, how they have entered Pennsylvania’s drug supply, and what makes them particularly dangerous, is not a task only for public health professionals. It is something that families of people who use opioids, first responders, people in recovery, and anyone who cares about someone at risk needs to be equipped to do. The information in this post is not meant to alarm. It is meant to prepare.

What Nitazenes Are

Nitazenes are a class of synthetic opioids belonging to the benzimidazole-opioid structural family. They were originally developed in the 1950s as potential pharmaceutical painkillers, but their extreme potency and toxicity prevented them from ever receiving clinical approval. For decades they existed as obscure entries in pharmacological research literature, of interest to chemists but irrelevant to anyone else.

That changed around 2019, when nitazenes began appearing in the illicit drug supply in the United States and other countries. The circumstances that brought them out of the laboratory and into the drug market are not unlike those that brought fentanyl: a demand for cheap, potent synthetic opioids that could be manufactured without the agricultural supply chains that heroin requires, combined with the chemical knowledge and manufacturing capacity to produce them at scale.

There is not a single nitazene. The term refers to a broad class of related compounds, each with slightly different chemical structures and significantly different potency profiles. Some nitazenes, such as isotonitazene and protonitazene, are estimated to be several times more potent than fentanyl. Others within the class have been found to be up to 40 times more potent than fentanyl. The variation within the class is part of what makes nitazenes particularly difficult to track and respond to, because different analogs require different detection methods, and traffickers can modify chemical structures to stay ahead of scheduling efforts.

Like fentanyl, nitazenes work by binding to opioid receptors in the brain and central nervous system, producing analgesia, sedation, and at sufficient doses, potentially fatal respiratory depression. Unlike fentanyl, they are not detectable by the fentanyl test strips that have become a common harm reduction tool. A person using a test strip to check their drugs for fentanyl will receive a negative result even if nitazenes are present.

What Pennsylvania Is Seeing

Pennsylvania has a specific and concerning history with nitazenes that predates the national attention the drug class has received.

Nitazene use in Pennsylvania’s illicit drug supply has been increasing since 2019, according to the state Department of Health. Pennsylvania issued a temporary scheduling of nitazenes for the first time in 2023, and has continued that process as the threat has persisted.

The Pennsylvania health department has confirmed at least 50 fatal overdoses associated with nitazenes since 2020, with a record 29 deaths in a single recent year. By comparison, fentanyl was associated with the deaths of more than 3,500 Pennsylvanians in 2023 alone. The raw numbers look different, but the trajectory matters as much as the current count, and nitazene-associated deaths in Pennsylvania have been rising year over year.

Those numbers are also almost certainly undercounts. Their true prevalence is largely unknown due to a lack of testing and reporting, according to Alex Krotulski, director of the Center for Forensic Science Research and Education, a Montgomery County-based lab that studies toxic adulterants in drugs and serves as a warning system for emerging illicit substances. Standard toxicology panels used in many Pennsylvania counties do not include nitazene testing, which means that overdose deaths involving nitazenes are likely being attributed to other substances or to undetermined causes.

In July 2025, the Shapiro Administration temporarily scheduled nitazenes as Schedule I controlled substances under Pennsylvania law, citing an imminent and continued hazard to public safety and noting that nitazenes have been responsible for numerous deaths in the state.

At the federal level, Pennsylvania Senator David McCormick introduced the Nitazene Control Act to permanently schedule the entire class of nitazenes under Schedule I of the federal Controlled Substances Act, with the goal of closing loopholes that traffickers exploit by slightly modifying chemical structures to produce technically unscheduled analogs.

The legislative response reflects the seriousness with which Pennsylvania officials are treating the nitazene threat. What it does not do, on its own, is make the drug supply safer for the people currently using street opioids in Pennsylvania.

How Nitazenes Are Entering the Drug Supply

Understanding how nitazenes reach people is important because it shapes who is at risk and how that risk can be reduced.

Nitazenes are entering the illicit supply through two primary routes. The first is as an adulterant in fentanyl, mixed into the existing opioid supply the same way xylazine has been. People using what they believe to be fentanyl may be unknowingly consuming a substance that is significantly more potent, with no way to detect it using standard testing methods.

The second route is through counterfeit prescription pills. Testing has found nitazenes in pills pressed to look like oxycodone, Percocet, and hydromorphone. Approximately one in six samples submitted as opioid press pills in recent testing has been found to contain a nitazene compound. This is a particularly alarming finding because counterfeit pills are used by people across a wide range of circumstances, including people who do not think of themselves as drug users in the traditional sense, people who believe they are obtaining legitimate prescription medications, and young people who are experimenting with substances they believe to be pharmaceutical.

Between 2023 and 2024, laboratory data showed a 17 percent rise in nitazene detections among fentanyl-positive drug samples, and in nearly all cases the substances were found together. This co-occurrence means that the risk of nitazene exposure is not separate from the risk of fentanyl exposure. It is layered on top of it, amplifying the danger of an already extremely dangerous drug supply.

International trafficking has contributed to the spread. A 2025 global alert noted that nitazenes were being shipped through international mail in small parcels, some containing enough for hundreds of lethal doses. The combination of extreme potency and small physical volume makes nitazenes well suited for smuggling in ways that bulkier substances are not.

Why Nitazenes Are Particularly Dangerous

Several specific features of nitazenes make them more dangerous than fentanyl in ways that go beyond raw potency.

Fentanyl test strips do not detect them. This is among the most practically significant facts about nitazenes for anyone in the harm reduction space or anyone who loves someone who uses street opioids. Standard fentanyl test strips do not detect nitazenes due to their different chemical structure, and most point-of-care drug checking requires specialized equipment to identify them. Nitazene immunoassay test strips do exist, but they are limited in the range of nitazene compounds they can detect and are not widely accessible. The harm reduction infrastructure that has been built around fentanyl test strip distribution provides meaningful but incomplete protection in a drug supply that now contains nitazenes.

Standard toxicology does not reliably catch them. Many medical examiner offices and hospital laboratories do not include nitazene testing in their standard panels, which means that overdose deaths and non-fatal overdoses involving nitazenes may not be identified as such. This gap in surveillance means that the scale of the problem in Pennsylvania is likely larger than the confirmed numbers reflect.

The potency variation within the class creates unpredictable risk. Because different nitazene analogs vary enormously in their potency, a person who has used a particular batch of nitazene-containing drugs without serious consequences may encounter a different batch with a significantly more potent compound and have no frame of reference for how dangerous it is. The variation within the class makes dose titration, already an irrelevant concept in illicit drug use, even more dangerous.

Naloxone response may require higher doses. Unlike xylazine, nitazenes are opioids, and naloxone does work to reverse nitazene overdoses. However, because some nitazenes are significantly more potent than fentanyl, a standard naloxone dose may be insufficient to fully reverse the overdose. Multiple doses may be required, and the window for effective naloxone administration may be shorter than in a fentanyl-only overdose given the speed and depth of respiratory depression that high-potency nitazenes can produce.

What Families Need to Understand

If you have a family member who is using street opioids in Pennsylvania, the nitazene situation adds urgency to conversations and decisions that may already feel overwhelming. A few things are worth understanding clearly.

The contamination of the drug supply with nitazenes is not something that informed or careful drug use can fully protect against. There is currently no widely accessible, reliable way for a person using street opioids to know whether nitazenes are present in what they have obtained. The risk is invisible and unpredictable in ways that even experienced opioid users cannot effectively manage.

This means that conversations about harm reduction, while still valuable and worth having, are not sufficient as a response to the nitazene threat. The most effective risk reduction available to someone using street opioids in Pennsylvania right now is treatment. Not because treatment is easy or immediate, but because treatment addresses the opioid use disorder that is driving exposure to a drug supply that has become more dangerous than at any previous point in the opioid crisis.

Naloxone should still be carried by anyone who is in proximity to someone using street opioids. Naloxone works on nitazenes. Having multiple doses available and being prepared to use them is important. But calling 911 immediately in any suspected overdose is equally important, because the speed and depth of nitazene-related respiratory depression may require emergency medical intervention beyond what naloxone alone provides.

If your family member has been resistant to conversations about treatment, the current state of the drug supply is a legitimate and factual reason to return to that conversation. You are not catastrophizing. The risk is real, it is documented, and it is increasing.

What First Responders Need to Know

For emergency medical personnel, law enforcement, and fire departments responding to overdose calls across Pennsylvania, nitazenes create specific challenges that are worth understanding.

Overdoses involving high-potency nitazenes may require multiple doses of naloxone. The standard protocol of administering naloxone and monitoring for response remains the right first step, but first responders should be prepared for cases where the initial dose produces minimal or slower-than-expected response and additional doses are warranted.

The absence of a positive fentanyl test does not mean the drug supply is safer. First responders who are familiar with fentanyl test strip results as a rough indicator of the drug landscape in their area should understand that nitazene-containing drugs will not trigger those strips. The drug supply can contain potent nitazenes while simultaneously producing negative fentanyl test results.

Documentation of suspected nitazene involvement in overdose cases contributes to the public health surveillance that allows the state to understand the scope of the problem. Given the known gaps in standard toxicology testing, clinical observations of unusual overdose presentations, including those that are more severe or less responsive to naloxone than typical fentanyl overdoses, are worth documenting carefully.

What People in Recovery Need to Know

For people in recovery from opioid use disorder, the nitazene situation is a meaningful data point in the ongoing calculus of why sustained recovery matters and why returning to street opioid use carries risks that are categorically different from what they were even a few years ago.

The drug supply that exists today is not the drug supply that existed at the beginning of most people’s opioid use disorders. It is more dangerous, more unpredictable, and more contaminated with substances that are harder to detect and respond to. This is not a moral argument for staying sober. It is a factual description of the environment that a return to use now involves.

For people who are working hard at recovery and want context for why that work matters, the nitazene situation is part of it. The landscape has shifted in ways that make the stakes of active opioid use disorder in Pennsylvania higher than they have ever been.

The Treatment Picture

For people who are currently using opioids in Pennsylvania and considering treatment, the nitazene situation reinforces rather than changes the fundamentals of what effective treatment involves.

Medication-assisted treatment with buprenorphine or methadone remains the most effective intervention for opioid use disorder. These medications reduce cravings, manage withdrawal, and significantly reduce exposure to the contaminated street drug supply that now contains nitazenes. The evidence base for medication-assisted treatment is strong and continues to grow, and there is no clinical rationale for withholding it from people who would benefit from it.

What the nitazene situation adds to the treatment picture is urgency. The window between deciding to seek help and actually entering treatment is a window of continued exposure to a drug supply that is measurably more dangerous than it was before. Shortening that window, by making the decision sooner and acting on it quickly, reduces exposure to a risk that is not theoretical.

Co-occurring mental health conditions, which are present in the majority of people with opioid use disorder and are often central to why the dependency developed, need to be addressed in treatment alongside the substance use. Depression, PTSD, anxiety, and trauma histories do not resolve because a person stops using opioids. They require their own clinical attention, and treatment that provides that attention produces significantly better outcomes than treatment that focuses on substance use alone.

How Silvermist Approaches the Evolving Drug Threat

At Silvermist Recovery, we provide residential and partial hospitalization treatment for adults at our campuses in Pittsburgh and the Poconos. We treat substance use disorders and co-occurring mental health conditions, and our clinical team stays current with the evolving landscape of the drug supply in Pennsylvania and the broader region.

The nitazene threat is part of the context in which we understand our work. The people who come to us for treatment are often coming from a drug supply that is more dangerous than anything that preceded it, and the care we provide needs to reflect that reality. This means thorough medical assessment at intake, medication-assisted treatment options for those who need them, and therapeutic programs that address the mental health conditions that so often sit beneath the surface of opioid use disorder.

We also offer gender-specific programming, LGBTQIA+ affirming care, veterans treatment through Project Resilience, and a comprehensive holistic therapy program, because we understand that the people who need treatment are not a monolith and that care which accounts for who a person actually is produces better outcomes than care that does not.

If you are concerned about yourself or someone you love, we encourage you to reach out. The drug supply in Pennsylvania is not becoming safer on its own, and waiting is not a neutral choice.

Contact Silvermist Recovery today to speak with our admissions team about what treatment looks like and what the right next step might be for your situation.